Thioxo-dihydroquinazolin-one Compounds as Novel Inhibitors of Myeloperoxidase.

ACS Med Chem Lett

Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia 30322, United States.

Published: October 2015

Myeloperoxidase (MPO) is a key antimicrobial enzyme, playing a normal role in host defense, but also contributing to inflammatory conditions including neuroinflammatory diseases such as Parkinson's and Alzheimer's. We synthesized and characterized more than 50 quinazolin-4(1H)-one derivatives and showed that this class of compounds inhibits MPO with IC50 values as low as 100 nM. Representative compounds showed partially reversible inhibition that was competitive with respect to Amplex Red substrate and did not result in the accumulation of MPO Compound II. Members of this group show promise for therapeutic development for the treatment of diseases in which inflammation plays a pathogenic role.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601060PMC
http://dx.doi.org/10.1021/acsmedchemlett.5b00287DOI Listing

Publication Analysis

Top Keywords

thioxo-dihydroquinazolin-one compounds
4
compounds novel
4
novel inhibitors
4
inhibitors myeloperoxidase
4
myeloperoxidase myeloperoxidase
4
myeloperoxidase mpo
4
mpo key
4
key antimicrobial
4
antimicrobial enzyme
4
enzyme playing
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!